| |
PRZOOM - /newswire/ -
Fremont, CA, United States, 2010/02/09 - AnaSpec, has announced the release of two new multiple sclerosis (MS)/experimental autoimmune encephalomyelitis (EAE) related ELISA assays kits, the SensoLyte® Anti-PLP(139-151) Assay Kit and the SensoLyte® Anti-PLP(178-191) Assay Kit.
|
| |
AnaSpec, the maker of the industry’s first and only colorimetric anti-MOG assay kits, has announced the release of two new multiple sclerosis (MS)/experimental autoimmune encephalomyelitis (EAE) related ELISA assays kits, the SensoLyte® Anti-PLP(139-151) Assay Kit and the SensoLyte® Anti-PLP(178-191) Assay Kit. These kits, precoated either with PLP (139-151) or PLP (178-191) peptide are optimized to detect mouse anti- PLP (139-151) or anti-PLP (178-191) IgG, respectively. The amount of IgG antibodies in mouse serum or cerebrospinal fluid is quantified using ELISA. Ample materials and reagents are provided to perform 80 assays in a 96-well plate format.
Proteolipid protein (PLP) is the most abundant protein in the central nervous system (CNS) myelin sheath and is highly conserved among species.1-2 PLP has a 50% hydrophobic amino acids content and a molecular weight of 30 kDa1. Mouse PLP (139-151) and PLP (178-191) are able to induce autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination.1-4 Autoantibody response to mouse PLP (139-151) and PLP (178-191) has been observed in induced experimental autoimmune encephalomyelitis (EAE) in B10.PL, C57BL/6, BALB/c, SJL, F1, and SWR mice strains.3-4 However, the exact pathological role and action of anti-mouse PLP (139-151) and anti-PLP (178-191) autoantibody is not well understood.1-4
References:
1. Tzakos, AG. et al. Curr. Med. Chem.12, 1569 (2005).
2. Miller, D. et al. Curr. Protocols Immunol .15.1.1.(2007)
3. Tuohy, V. et al. J. Neuroimmunol.. 39,67 (2003).
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
About Eurogentec
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit Eurogentec website.
|
ping[.]anaspec.com 
